News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
773,873 Results
Type
Article (76339)
Company Profile (614)
Press Release (696920)
Section
Business (214138)
Career Advice (3647)
Deals (37924)
Drug Delivery (105)
Drug Development (87707)
Employer Resources (179)
FDA (17333)
Job Trends (16687)
News (369122)
Policy (36762)
Tag
Academia (2966)
Africa (1126)
Alliances (52657)
Alzheimer's disease (1240)
Approvals (17246)
Arizona (174)
Artificial intelligence (84)
Asia (45462)
Australia (8110)
Bankruptcy (357)
Best Places to Work (12227)
Biotechnology (431)
C2C Services and Suppliers (86156)
California (1943)
Canada (919)
Cancer (467)
Career advice (3091)
Cell therapy (138)
China (147)
Clinical research (68206)
Collaboration (144)
Colorado (80)
Compensation (77)
Connecticut (80)
COVID-19 (2730)
Cystic fibrosis (77)
Data (246)
Diabetes (88)
Diagnostics (6464)
Drug pricing (80)
Earnings (81810)
Employer resources (153)
Europe (105278)
Events (121165)
Executive appointments (147)
FDA (17542)
Florida (265)
Funding (144)
Gene therapy (104)
GLP-1 (607)
Government (4929)
Healthcare (20605)
Hotbed/Location (506142)
Illinois (305)
Indiana (158)
Infectious disease (2760)
Inflammatory bowel disease (100)
Interviews (702)
IPO (17362)
Job creations (4624)
Job search strategy (2553)
Kansas (99)
Layoffs (464)
Legal (8798)
Lung cancer (112)
Manufacturing (97)
Maryland (415)
Massachusetts (1670)
Medical device (14189)
Medtech (14194)
Mergers & acquisitions (20406)
Metabolic disorders (286)
Michigan (135)
Minnesota (235)
Neuroscience (1393)
New Jersey (584)
New York (596)
NextGen Class of 2024 (7536)
Non-profit (5042)
North Carolina (693)
Northern California (819)
Obesity (170)
Ohio (109)
Opinion (233)
Patents (73)
Pennsylvania (585)
People (62148)
Pharmaceutical (118)
Phase I (21058)
Phase II (29693)
Phase III (22394)
Pipeline (106)
Podcasts (73)
Postmarket research (3219)
Preclinical (9400)
Press Release (72)
Rare diseases (140)
Real estate (6967)
Recruiting (70)
Regulatory (24043)
Research institute (2624)
Resumes & cover letters (578)
South America (1485)
Southern California (745)
Startups (3965)
Texas (249)
United States (9040)
Vaccines (546)
Washington State (275)
Weight loss (161)
Date
Today (28)
Last 7 days (683)
Last 30 days (2195)
Last 365 days (39842)
2024 (27664)
2023 (42500)
2022 (53839)
2021 (58676)
2020 (57630)
2019 (51246)
2018 (38966)
2017 (36127)
2016 (36480)
2015 (42390)
2014 (36799)
2013 (34153)
2012 (34716)
2011 (34892)
2010 (34197)
773,873 Results for "the new england journal of medicine".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
Oncocyte Corporation, a precision diagnostics company, announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine.
May 30, 2024
·
8 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
BioMidwest
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine.
March 13, 2024
·
8 min read
BioMidwest
The New England Journal of Medicine Publishes Complete Data from ENRICH, the First Positive Trial to Improve Functional and Economic Outcomes for Intracerebral Hemorrhage (ICH)
NICO Corporation, a pioneer and leader in minimally invasive parafascicular surgery (MIPS), today announced the entire results of the ENRICH (Early MiNimally-invasive Removal of ICH) trial have been published in the New England Journal of Medicine.
April 11, 2024
·
8 min read
Drug Development
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
Madrigal Pharmaceuticals, Inc. today announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine.
February 8, 2024
·
12 min read
Drug Development
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Intellia Therapeutics, Inc. announced that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine.
January 31, 2024
·
7 min read
Drug Development
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC).
February 21, 2024
·
8 min read
Drug Development
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced publication in the New England Journal of Medicine (NEJM) of the REVIVE Phase 2 study (NCT04057040) results evaluating the efficacy and safety of rusfertide in polycythemia vera (PV), a myeloproliferative neoplasm affecting approximately 160,000 patients in the United States (US).
February 21, 2024
·
9 min read
1 of 77,388
Next